PRLD · XBRL financial data

Prelude Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PRLD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	—	—	—	—	7,000	12,140
Research and development	48,177	86,778	92,889	103,393	117,995	94,300
General and administrative	10,586	26,957	30,651	28,884	28,719	22,406
Total operating expenses	58,763	113,735	123,540	132,277	146,714	116,706
Operating income (loss)	(58,763)	(113,735)	(123,540)	(132,277)	(139,714)	(104,566)
Other income (expense)	1,834	2,041	8,102	10,445	12,541	5,068
Income tax expense (benefit)	—	—	—	—	0	0
Net income (loss)	(56,929)	(111,694)	(115,438)	(121,832)	(127,173)	(99,498)
Earnings per share, basic USD per share	—	(2.43)	(2.44)	(2.02)	(1.68)	(1.29)
Earnings per share, diluted USD per share	—	(2.43)	(2.44)	(2.02)	(1.68)	(1.29)
Weighted average shares, basic thousands of shares	—	46,050	47,372	60,357	75,806	76,956
Weighted average shares, diluted thousands of shares	—	46,050	47,372	60,357	75,806	76,956

Fiscal years (PRLD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	218,309	31,828	30,605	25,291	12,474	35,256
Marketable securities	—	259,405	171,123	207,644	121,140	67,958
Prepaid and other current assets	2,500	3,882	2,652	2,654	2,281	2,478
Total current assets	220,809	295,115	204,380	235,589	135,895	105,692
Property and equipment, net	2,480	3,929	4,908	7,325	6,767	5,113
Right-of-use asset	—	1,707	1,792	30,412	28,699	27,165
Total assets	223,590	305,098	220,500	277,665	175,515	141,315
Accounts payable	3,920	7,840	6,777	4,580	7,732	3,983
Accrued liabilities	7,455	9,621	13,093	15,768	15,209	12,533
Total current liabilities	11,375	19,201	21,702	21,829	25,641	52,994
Lease liability, non-current	—	—	—	15,407	15,325	15,045
Total liabilities	11,407	19,201	25,063	40,575	44,056	72,678
Accumulated deficit	(107,426)	(219,120)	(334,558)	(456,390)	(583,563)	(683,061)
Total stockholders' equity	212,183	285,897	195,437	237,090	131,459	68,637
Total liabilities and equity	223,590	305,098	220,500	277,665	175,515	141,315
Common shares outstanding (cover page) thousands of shares	46,586	47,632	47,913	54,921	55,155	63,002

Fiscal years (PRLD's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(56,929)	(111,694)	(115,438)	(121,832)	(127,173)	(99,498)
Stock-based compensation	5,583	20,931	25,144	25,616	21,345	11,913
Depreciation and amortization	542	915	1,324	1,169	1,772	1,711
Net cash from operating activities	(46,177)	(83,531)	(83,729)	(107,063)	(102,888)	(56,302)
Purchases of property and equipment	621	2,323	3,019	3,513	764	67
Net cash from investing activities	(621)	(263,803)	81,691	(34,646)	90,191	53,459
Proceeds from issuing common stock	—	161,424	—	—	—	—
Net cash from financing activities	246,228	164,897	815	136,395	(120)	24,816
Net change in cash	199,430	(182,437)	(1,223)	(5,314)	(12,817)	21,973

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Prelude Therapeutics	26,329	5,704	(15,574)*	79.8M	9.7 quarters	Q2 FY26 10-QJun 30, 2026
Edesa Biotech	10,300	not reported	(3,083)*	9.6M	3.3 quarters	Q3 FY26 10-QJun 30, 2026
X4 Pharmaceuticals	185,801	2,879	(20,186)*	102.1M	9.2 quarters	Q3 FY26 10-QSep 30, 2026
Akari Therapeutics	7,694	not reported	(3,109)*	155.8B	2.5 quarters	Q2 FY26 10-QJun 30, 2026
GeoVax Labs	3,143	not reported	(3,658)*	7.4M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
ProPhase Labs	20	1,011	(78)*	15.6M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Pluri	3,529	335*	(4,443)*	12.3M	0.8 quarters	Q4 FY26 10-KJun 30, 2026
Earth Science Tech	631	9,026	707	287.6M	—	Q1 FY27 10-QJun 30, 2026
CalciMedica	18,617	not reported	(4,620)*	34.1M	4.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.